sar425899 glucagon glp-1 dual agonist sanofi The current significance and prospects for the use of receptor agonism GLP-1/Glucagon The Road towards Triple Agonists:
Description
The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status
Methods Adults (18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index
More on, ADA and AACE Guidelines prefer GLP1RA over DPP4i for patients with established ASCVD or indicato...
Learn why people explore it and what to consider before trying it.
Fayetteville NC Ozempic Weight Loss Injections at Cape Fear Physical Medicine & Rehab
This study evaluates the efficacy and safety of arGLP-1 in patients with IWL or WR after BS
